Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer

Jeffrey R. Infante, Amita Patnaik, Claire F. Verschraegen, Anthony J. Olszanski, Montaser Shaheen, Howard A. Burris, Anthony W. Tolcher, Kyriakos P. Papadopoulos, Muralidhar Beeram, Scott M. Hynes, Jennifer Leohr, Aimee Bence Lin, Lily Q. Li, Anna McGlothlin, Daphne L. Farrington, Eric H. Westin, Roger B. Cohen

Research output: Contribution to journal › Article › peer-review

20 Scopus citations

Fingerprint

Dive into the research topics of 'Two Phase 1 dose-escalation studies exploring multiple regimens of litronesib (LY2523355), an Eg5 inhibitor, in patients with advanced cancer'. Together they form a unique fingerprint.

Pharmacology, Toxicology and Pharmaceutical Science